{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T13:41:15Z","timestamp":1649684475113},"reference-count":3,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T00:00:00Z","timestamp":1645574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00108-022-01273-4","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:03:15Z","timestamp":1645617795000},"page":"170-174","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["60\/m \u2013 \u00dcberpr\u00fcfung der bestehenden Therapie eines Diabetes mellitus Typ\u00a02"],"prefix":"10.1007","volume":"63","author":[{"given":"M.","family":"Menzen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"1273_CR1","unstructured":"(2020) Nationale Versorgungsleitlinie Typ-2-Diabetes. Langfassung. 2. Auflage. https:\/\/www.leitlinien.de\/nvl\/diabetes (Konsultationsfassung). Zugegriffen: 06.08.2021"},{"key":"1273_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s11428-021-00734-y","author":"M Menzen","year":"2021","unstructured":"Menzen\u00a0M (2021) Individuelle Therapieziele f\u00fcr Menschen mit Diabetes. Diabetologe. https:\/\/doi.org\/10.1007\/s11428-021-00734-y","journal-title":"Diabetologe"},{"issue":"Suppl 2","key":"1273_CR3","first-page":"S192","volume":"13","author":"H Hauner","year":"2018","unstructured":"Hauner\u00a0H et\u00a0al (2018) S2 Praxisempfehlung: Adipositas und Diabetes mellitus. Diabetologie 13(Suppl 2):S192\u2013S198","journal-title":"Diabetologie"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-022-01273-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-022-01273-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T13:09:49Z","timestamp":1649682589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-022-01273-4"}},"subtitle":["Vorbereitung auf die Facharztpr\u00fcfung: Fall 130"],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":3,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["1273"],"URL":"https:\/\/doi.org\/10.1007\/s00108-022-01273-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"assertion":[{"value":"19 January 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Menzen: Referentenhonorare\/Reisekosten: AstraZeneca, Boehringer Ingelheim, MSD, Novo Nordisk, Novartis, Eli Lilly, Deutsche Diabetes Gesellschaft, \u00c4rztekammer Nordrhein. Bezahlter Berater\/interner Schulungsreferent: Novo Nordisk, Servier, Novartis, Bayer AG. Nichtfinanzielle Interessen: Chefarzt Innere Medizin\u00a0\u2013 Diabetologie, Gemeinschaftskrankenhaus Bonn. Mitgliedschaften: Deutsche Diabetes Gesellschaft, Deutsche Gesellschaft f\u00fcr Innere Medizin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patienten zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"The supplement containing this article is not sponsored by industry.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}